Eli Lilly and Company
Eli Lilly and Company (LLY) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · LLY · as of Jun 8, 2026
Key Statistics
Explore Eli Lilly and Company Data
lly stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 45 · Buy rate: 73.3%
The LLY analyst consensus is Buy, based on ratings from 45 Wall Street analysts over the past 3 months. The average 12-month price target is $1266.17, representing +11.91% upside from the current price of $1131.42.
Competitors & Peers
lly competitorsLLY
ABBV
AMGN
AZN
GILD
JNJStock Performance
Full HistoryAbout Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro,…
what is eli lilly and company · lly stock overview · eli lilly and company company profile · who is eli lilly and company ceo · lly NYSE · eli lilly and company headquarters · eli lilly and company business segments
About Stock Overview & Key Data
Eli Lilly and Company (LLY) is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE since Jun 1, 1972. As of the latest trading session, LLY stock price is $1131.42, with a market capitalization of $1.07T. The stock has returned +46.23% over the past 12 months and +5.28% year-to-date.
According to 45 Wall Street analysts, the consensus rating for Eli Lilly and Company stock is Buy, with an average 12-month price target of $1266.17. In fiscal year 2025, Eli Lilly and Company reported revenue of $65.2B and net income of $20.6B. For detailed data — including Eli Lilly and Company revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Eli Lilly and Company (LLY) stock price is $1131.42. The stock is traded on NYSE under the ticker symbol LLY. The 52-week range is $623.78 – $1166.29.